Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept

Ahmad M. Mansour, Khalil El Jawhari, J Fernando Arevalo

Research output: Contribution to journalArticle

Abstract

Purpose: The aim of this study was to investigate the possibility of decreasing the number of intravitreal anti-VEGF by peripheral pan-retinal photocoagulation (PPRP) in managing diabetic macular edema (DME) in a subcategory of patients who cannot comply to strict anti-VEGF follow-up protocols. Materials and methods: This is a pilot prospective study. Consecutive patients with naïve DME were offered the choice of treatment and extend intravitreal ziv-aflibercept if they showed willingness for good compliance or PPRP with modified pro re nata intravitreal injections. Results: Six eyes of 3 patients had PPRP versus 4 eyes of 4 patients had injections only. The number of anti-VEGF injections was markedly decreased when PPRP was administered from a mean number of injections of 16.8 (range 13–21; mean follow-up 24.3 months) to a mean number of 4.5 (range 0–8; mean follow-up 33.7 months). Mean initial central macular thickness (CMT) was 462.0 mm in the injection only group vs 457.3 mm in the PPRP group. Mean final CMT was 462.0 in the injection only group vs 350.0 in the PPRP group. Baseline and final mean logMAR (Snellen equivalent) best-corrected visual acuity was initially and finally 0.84 (20/137) and 0.60 (20/80) in the injection only group and 0.70 (20/100) and 0.69 (20/98) in the PPRP group, respectively. The monthly cost for the PPRP group was one-third of the monthly cost for the injection only group. Conclusion: PPRP allowed for a decrease in the number of intravitreal anti-VEGF injections in selected DME patients (sick, difficult to ambulate, financial burden, and fear of injections).

Original languageEnglish (US)
Pages (from-to)685-694
Number of pages10
JournalClinical Ophthalmology
Volume13
DOIs
StatePublished - Jan 1 2019

Fingerprint

Macular Edema
Light Coagulation
Injections
Vascular Endothelial Growth Factor A
aflibercept
Costs and Cost Analysis
Intravitreal Injections
Visual Acuity
Fear
Prospective Studies

Keywords

  • Diabetic retinopathy
  • Laser therapy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept. / Mansour, Ahmad M.; El Jawhari, Khalil; Arevalo, J Fernando.

In: Clinical Ophthalmology, Vol. 13, 01.01.2019, p. 685-694.

Research output: Contribution to journalArticle

@article{079f6dbcf6ca427aa49548092ddc6bb0,
title = "Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept",
abstract = "Purpose: The aim of this study was to investigate the possibility of decreasing the number of intravitreal anti-VEGF by peripheral pan-retinal photocoagulation (PPRP) in managing diabetic macular edema (DME) in a subcategory of patients who cannot comply to strict anti-VEGF follow-up protocols. Materials and methods: This is a pilot prospective study. Consecutive patients with na{\"i}ve DME were offered the choice of treatment and extend intravitreal ziv-aflibercept if they showed willingness for good compliance or PPRP with modified pro re nata intravitreal injections. Results: Six eyes of 3 patients had PPRP versus 4 eyes of 4 patients had injections only. The number of anti-VEGF injections was markedly decreased when PPRP was administered from a mean number of injections of 16.8 (range 13–21; mean follow-up 24.3 months) to a mean number of 4.5 (range 0–8; mean follow-up 33.7 months). Mean initial central macular thickness (CMT) was 462.0 mm in the injection only group vs 457.3 mm in the PPRP group. Mean final CMT was 462.0 in the injection only group vs 350.0 in the PPRP group. Baseline and final mean logMAR (Snellen equivalent) best-corrected visual acuity was initially and finally 0.84 (20/137) and 0.60 (20/80) in the injection only group and 0.70 (20/100) and 0.69 (20/98) in the PPRP group, respectively. The monthly cost for the PPRP group was one-third of the monthly cost for the injection only group. Conclusion: PPRP allowed for a decrease in the number of intravitreal anti-VEGF injections in selected DME patients (sick, difficult to ambulate, financial burden, and fear of injections).",
keywords = "Diabetic retinopathy, Laser therapy, Vascular endothelial growth factor",
author = "Mansour, {Ahmad M.} and {El Jawhari}, Khalil and Arevalo, {J Fernando}",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/OPTH.S199411",
language = "English (US)",
volume = "13",
pages = "685--694",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept

AU - Mansour, Ahmad M.

AU - El Jawhari, Khalil

AU - Arevalo, J Fernando

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: The aim of this study was to investigate the possibility of decreasing the number of intravitreal anti-VEGF by peripheral pan-retinal photocoagulation (PPRP) in managing diabetic macular edema (DME) in a subcategory of patients who cannot comply to strict anti-VEGF follow-up protocols. Materials and methods: This is a pilot prospective study. Consecutive patients with naïve DME were offered the choice of treatment and extend intravitreal ziv-aflibercept if they showed willingness for good compliance or PPRP with modified pro re nata intravitreal injections. Results: Six eyes of 3 patients had PPRP versus 4 eyes of 4 patients had injections only. The number of anti-VEGF injections was markedly decreased when PPRP was administered from a mean number of injections of 16.8 (range 13–21; mean follow-up 24.3 months) to a mean number of 4.5 (range 0–8; mean follow-up 33.7 months). Mean initial central macular thickness (CMT) was 462.0 mm in the injection only group vs 457.3 mm in the PPRP group. Mean final CMT was 462.0 in the injection only group vs 350.0 in the PPRP group. Baseline and final mean logMAR (Snellen equivalent) best-corrected visual acuity was initially and finally 0.84 (20/137) and 0.60 (20/80) in the injection only group and 0.70 (20/100) and 0.69 (20/98) in the PPRP group, respectively. The monthly cost for the PPRP group was one-third of the monthly cost for the injection only group. Conclusion: PPRP allowed for a decrease in the number of intravitreal anti-VEGF injections in selected DME patients (sick, difficult to ambulate, financial burden, and fear of injections).

AB - Purpose: The aim of this study was to investigate the possibility of decreasing the number of intravitreal anti-VEGF by peripheral pan-retinal photocoagulation (PPRP) in managing diabetic macular edema (DME) in a subcategory of patients who cannot comply to strict anti-VEGF follow-up protocols. Materials and methods: This is a pilot prospective study. Consecutive patients with naïve DME were offered the choice of treatment and extend intravitreal ziv-aflibercept if they showed willingness for good compliance or PPRP with modified pro re nata intravitreal injections. Results: Six eyes of 3 patients had PPRP versus 4 eyes of 4 patients had injections only. The number of anti-VEGF injections was markedly decreased when PPRP was administered from a mean number of injections of 16.8 (range 13–21; mean follow-up 24.3 months) to a mean number of 4.5 (range 0–8; mean follow-up 33.7 months). Mean initial central macular thickness (CMT) was 462.0 mm in the injection only group vs 457.3 mm in the PPRP group. Mean final CMT was 462.0 in the injection only group vs 350.0 in the PPRP group. Baseline and final mean logMAR (Snellen equivalent) best-corrected visual acuity was initially and finally 0.84 (20/137) and 0.60 (20/80) in the injection only group and 0.70 (20/100) and 0.69 (20/98) in the PPRP group, respectively. The monthly cost for the PPRP group was one-third of the monthly cost for the injection only group. Conclusion: PPRP allowed for a decrease in the number of intravitreal anti-VEGF injections in selected DME patients (sick, difficult to ambulate, financial burden, and fear of injections).

KW - Diabetic retinopathy

KW - Laser therapy

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=85067560980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067560980&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S199411

DO - 10.2147/OPTH.S199411

M3 - Article

C2 - 31114146

AN - SCOPUS:85067560980

VL - 13

SP - 685

EP - 694

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -